Summary Human glioma usually shows intrinsic multidrug resistance because of the blood-brain barrier (BBB), in which membraneassociated P-glycoprotein (P-gp), encoded by the human multidrug resistance gene MDR1, plays a role. We studied drug sensitivity to vincristine (VCR), doxorubicin (DOX) and nimustine (ACNU) in both intracerebrally and subcutaneously xenotransplanted human glioma. We examined the levels of MDR1 and murine mdr3 gene expression in the xenografts by reverse transcriptase polymerase chain reaction and the localization of P-gp by immunohistochemistry. Six of seven subcutaneously transplanted xenografts (scX) were sensitive to the above three drugs. In contrast, all three intracerebrally transplanted human glioma xenografts (icX) were resistant to P-gp-mediated drugs VCR and DOX, but were sensitive to the non-P-gp-mediated drug ACNU. Neither icX nor scX showed any MDR1 expression. Intracerebrally transplanted human glioma xenografts showed an increased level of murine mdr3 gene expression, whereas scX showed only faint expression. The localization of P-gp was limited to the stromal vessels in icX by immunohistochemistry, whereas scX expressed no P-gp. Our findings suggest that the P-gp expressed on the stromal vessels in icX is a major contributing factor to multidrug resistance in human glioma in vivo.
Total removal of glioma is clinically difficult as the borders are ill defined. In addition, glioma shows intrinsic multidrug resistance to anti-cancer agents, and chemotherapy for glioma is thus unsuccessful (Edwards et al, 1980; Komblith et al, 1988) . Various mechanisms, including the blood-brain barrier (BBB), have been considered to be involved in the multidrug resistance of glioma.
Certain ultrastructural features, including the absence of fenestration and the presence of tight junctions, are considered to characterize the BBB (Reese et al, 1967; Long, 1970) . However, it has been reported (Levin, 1980) that hydrophobic anti-cancer agents such as vinca alkaloids and doxorubicin (DOX) do not easily enter the brain, although other hydrophobic molecules readily passed through the BBB. Thus, it appears that morphological BBB structures cannot completely explain the multidrug resistance in human glioma.
Some studies have indicated that the membrane-associated protein P-glycoprotein (P-gp) , encoded by human multidrug resistance gene MDRJ, is related to the multidrug resistance phenotype in human neoplasms (Chen et al, 1986; Gros et al, 1986) , and that P-gp is a component of the BBB in the normal brain (Tatsuta et al, 1992) . We have revealed that, in human glioma, P-gp is expressed not on the tumour cells but on the capillary blood vessels as determined by immunohistochemical and molecular biological methods (Tanaka et al, 1994 ).
In our other previous report, almost all the glioma xenografts subcutaneously transplanted in the nude mice were curiously sensitive to P-gp-mediated anti-cancer drugs (vincristine, VCR and DOX) without MDRJ expression (Abe et al, 1994a) , whereas these drugs are usually ineffective in clinical cases.
In this study, we performed intracerebral (icX) and subcutaneous (scX) transplantation of human glioma into nude mice to analyse the differences in chemosensitivity to anti-cancer drugs between clinical glioma and scX. We studied the chemosensitivity in vivo and the levels of expression of human MDR] and murine mdr3 (also called mdrla) gene in these glioma xenografts. We also examined the localization of P-gp in these glioma xenografts by immunohistochemistry. We discuss here the mechanisms of intrinsic multidrug resistance of glioma in relation to stromal endothelial P-gp expression in vivo.
MATERIALS AND METHODS Human glioma xenografts and cell lines
Seven human glioma xenografts were established from primary glioma specimens obtained from patients in whom there had been no preceding chemotherapy (Table 1) . The xenografts were maintained by serial subcutaneous transplantation in nude mice (BALB/c-nu/nu, Clea Japan, Tokyo). The xenografts were used at 10-20 passages. We obtained xenografts from mice after they had been deeply anaesthetized with chloroform. The drug-sensitive epidermoid carcinoma cell line KB3-1 and its resistant derivative KB8-5 were cultured in Dulbecco's modified Eagle minimal essential medium supplemented with 5% fetal bovine serum at 37°C in a fully humidified 95% air, 5% carbon dioxide atmosphere. (Shionogi, Osaka) and ACNU (Sankyo, Tokyo) were purchased from the sources shown. All drugs were dissolved in saline and used for in vivo chemosensitivity tests. We performed in vivo chemosensitivity tests on seven scX (Epe-1, GL-1, GL-2, GL-3, GL-5, GL-7, and GL-8), according to the procedures reported previously (Inaba et al, 1989; Abe et al, 1996a,b) . The nude mice were used at 6-8 weeks of age in accordance with the animal care guidelines of the Central Institute for Experimental Animals. Six female mice (BALB/c-nu/nu) bearing xenografts (tumour volume: 100-300 mm3) were given the maximum tolerated dose (MTD) of VCR (1.6 mg kg-') or DOX (12 mg kg-'). Growth of the tumour xenografts was measured by the relative tumour volume (RV), which was expressed as RV = V,4/V0, where V14 is the tumour volume at day 14 and V0 is the initial tumour volume when the treatment was started (day 0). The effects of the drugs are represented by RV of the xenografts, and the T/C% values were defined as the ratio of RV of the treated tumour xenografts to controls. Evaluation as 'sensitive' was defined based on statistical significance determined by the Mann-Whitney U-test (P < 0.01, one-sided).
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We also examined in vivo chemosensitivity in three icX (GL-2, GL-5, and GL-8), according to the previously reported method (Ausman et al, 1970; Shapiro et al, 1979; 1981) . When the animals showed severe wasting and were apparently moribund owing to intracerebral tumour growth, they were not observed further and the day of sacrifice was recorded to estimate life span according to the UKCCCR guidelines (Workman et al, 1988) . Surviving animals were sacrificed at the end of the experiment and sectioned for microscopic examination of tumour foci. The glioma xenograft specimens were removed from nude mice that had been deeply anaesthetized, and were immediately suspended in Ham's FlO culture medium. For intracerebral inoculation, 1 x 106 cells (in 0.025 ml) were injected percutaneously into the right cerebral hemisphere of nude mice using a 27-gauge needle. Six nude mice bearing the icX were intravenously treated with the MTD of each drug 5 days after inoculation. Drug sensitivity was represented by determining the percentage increase in lifespan (ILS) of the treated nude mice compared with controls. The significance of differences of ILS between treated and control mice was statistically tested by Student's t-test. Reverse transcriptase polymerase chain reaction (RT-PCR) The levels of expression of MDRJ transcripts were determined by the modified reverse transcriptase polymerase chain reaction (RT-PCR) procedure as described previously (Noonan et al, 1990; Abe et al, 1994b) . Normal human tissues (brain and kidney) were obtained by major surgery after obtaining the patients' informed consent. RT-PCR amplified a 243-bp fragment of MDR] cDNA. We estimated MDR] expression level in comparison with that of the housekeeping gene P2-microglobulin (IB2m).
We also prepared sets of specific primers for murine mndr3 (#M; sense, CATGGCTGGATCAGTGT'TTCTAGA, residues 3391-3415; antisense, GCAGTGAGTCGATGAACTGGTGGA, residues 3585-3608), and for murine ,B2m (#N; sense, GCAAG-GACTGGTCT'l'CTATA, residues 3144-3164; antisense, GCAT-GACAGTATGGCCGAGCC, residues 3223-3243) (Pames et al, 1982; Gros et al, 1988) . RT-PCR with these amprimers revealed a 218-bp segment of murine mdr3. The PCR products blotted on a membrane (Zeta Probe, BioRad) were detected by hybridization with synthetic oligonucleotide probes (GCCGTGTCTCATGAG-GAGATTGTG, residues 3518-3541, for #M; CTGATACATACGC-CTGCAGAG, residues 3217-3240, for #N) labelled with 32p.
Immunohistochemistry P-gp-positive tumour cells were analysed immunohistochemically with the anti-P-gp polyclonal antibody Ab-I (Oncogene Science) (Toth et al, 1994; Abe et al, 1996a) . Tumour sections were incubated with Ab-1, peroxidase-conjugated F(ab')2 of donkey anti-rabbit IgG (Amersham), rabbit monoclonal peroxidase-anti-peroxidase complex (Dako) and peroxidase-conjugated F(ab')2 fragments. The products were visu'alized with 3,3'-diaminobenzidine tetrahydrochloride. Table 2 summarizes the growth features of the scX, including relative tumour volume, T/C%, and Mann-Whitney U-test results (P < 0.01, one-sided). All seven scX showed T/C% values significantly less than 35%, and were thus considered to be sensitive to VCR and ACNU. Six of seven scX were also sensitive to DOX (T/C% < 32%). Only one scX (GL-5) showed a relatively high T/C% value to DOX (66%). The glioma scX showed high response rates of 100%, 100% and 86% to VCR, ACNU and DOX respectively. The maximum volume of tumour xenograft did not exceed 10% of the weight of the mouse (data not shown).
RESULTS

In vivo chemosensitivity test
The drug sensitivity of icX is shown in Table 3 . None of the three icX treated with VCR and DOX showed any significant elongation of the ILS (less than 55%), whereas the icX treated with ACNU showed remarkably high values for the ILS. Significant effects of ACNU on the glioma icX were also confirmed by statistical analysis by Student's t-test (P < 0.01).
Expression of MDR1
The human MDRJ-specific amprimers did not amplify murine mdr cDNA from normal murine tissues (brain, heart, lung, kidney, liver, spleen), although the sense and antisense primers showed Figure 2C) . scX, xenografts transplanted intracerebrally; icX, xenografts transplanted subcutaneously.
96% and 75% homology, respectively, with the murine mdr3 gene ( Figure IA) . We thus avoided amplification of murine mdr gene transcripts contaminating the tumour xenografts. Neither human glioma scX nor icX expressed MDR] (Table 4, Figure 1B ). Colon and pancreatic cancer xenografts uniformly retained levels of MDRJ gene expression similar to those in the original carcinomas (data not shown).
Expression of murine mdr3 gene
Murine mdr3-specific amprimers did not amplify the human MDRJ cDNA from normal human tissues (brain and kidney, Figure 2A ), although both sense and antisense primers revealed 67% homology with the human MDRJ gene. We thus specifically determined murine mdr3 gene transcripts with these amprimers. The amount of the PCR product of murine mdr3 was proportional to the initial template cDNA reverse transcribed from mRNA under our experimental conditions.
We quantitatively analysed the RT-PCR of mdr3 mRNA in murine brain, according to the modified procedures reported previously (Abe et al, 1993; 1994b) . The specific mdr3 products were also amplified exponentially by 22-32 PCR cycles (data not shown). The results suggested that mdr3 gene expression can be semiquantified by 28 cycles of RT-PCR with 500 ng of RNA. The icX showed significantly stronger mdr3 expression than normal murine brain ( Figure 2B ), whereas three of seven scX showed only faint levels of mdr3 expression ( Figure 2C ).
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We examined the localization of P-gp in human glioma of icX and scX. The localization of P-gp was limited to the stromal vessels in icX by immunohistochemistry (Figure 3 ), while the scX expressed no P-gp (Table 4) . P-gp was produced specifically on the capillary blood vessels, whereas neither tumour nor normal glial cells showed P-gp expression.
DISCUSSION
Human glioma usually shows intrinsic multidrug resistance to various anti-cancer agents. The multidrug-resistance phenomenon of glioma has been explained by the presence of the BBB on the stromal vessels. Chemotherapy with nitrosoureas, such as BCNU and ACNU, has been shown to be effective in glioma, whereas such anticancer drugs as VCR and DOX were not successful (Edwards et al, 1980; Komblith et al, 1988) . Previous studies have indicated that glioma xenografts, transplanted subcutaneously into host animals, were uniformly sensitive to such anti-cancer drugs, as VCR, DOX and ACNU in vivo (Maruo et al, 1990; Abe et al, 1994a) .
In this study, we examined the drug sensitivity of human glioma scX and icX in vivo to examine the above discrepancy between the clinical drug sensitivity of glioma and the experimental drug sensitivity of scX. The icX was relatively resistant to VCR and DOX (ILS% < 55%), and was sensitive only to ACNU (ILS% 2 137%). The icX reflected the clinical drug sensitivity of glioma. However, scX were sensitive to all three anti-cancer drugs (T/C% < 66%).
Several studies have indicated that P-gp constitutes part of the BBB (Thiebaut et al, 1987) , whereas some studies have shown that the expression of P-gp is limited to stromal capillary endothelial cells (Cordon-Cardo et al, 1989; Sugawara et al, 1990; Hegmann et al, 1992 , Tanaka et al, 1994 . However, others have suggested that P-gp overexpression in glioma cells contributes to MDR (Matsumoto et al, 1991; Nabors et al, 1991; Becker et al, 1991) . Although these studies employed immunohistochemical methods using anti-P-gp monoclonal antibodies, the localization and apparent function of P-gp in the normal brain and glioma were in conflict. P-gp or MDR] gene overexpression in solid tumour cells is generally thought to be an essential mechanism of multidrug resistance to hydrophobic anti-cancer agents (Gottesman et al, 1991) . In the present study, neither the scX nor icX of human glioma revealed MDR] expression by the RT-PCR assay. Murine mdr3 expression was enhanced in the icX compared with the normal murine brain, whereas the scX did not show significant enhancement of mdr3 expression. By immunohistochemical analysis, we confirmed limited P-gp expression not on tumour cells, but on capillary blood vessel walls.
Replacement of the human cerebral stroma, including blood vessels, by the murine subcutaneous stroma resulted in the loss of MDR] expression in the human glioma xenografts (Tanaka et al, 1994) . This molecular biological finding in glioma xenografts is consistent with the limited localization on the endothelial cells described above.
Murine mdr3 expression was enhanced in the icX compared with the normal murine brain, whereas the scX did not show significant enhancement of mdr3 expression. Schinkel et al (1994) reported that the expression of the murine mdr3 gene was preferentially related to multidrug resistance in murine brain. We confirmed that the level of mdr3 gene expression was higher than that of murine mdrl (also called mdrlb) in normal murine brain and in human glioma xenografts (data not shown). Our results support the idea that murine P-gp, encoded by mdr3, contributed to the multidrug resistance of the human glioma icX in vivo. The reversal of P-gp function produced by anti-P-gp monoclonal antibody, or by various compounds such as calcium channel antagonists, calmodulin inhibitors and cyclosporins, has overcome multidrug resistance in many tumours in vitro and in vivo (Boesch et al, 1991; Kadam et al, 1992; Mickisch et al, 1992; Miyamoto et al, 1993) . The results presented here suggest that glioma cells are themselves sensitive to VCR, DOX and ACNU, and that circumvention of the BBB-like function of P-gp could allow successful chemotherapy with these conventional anticancer agents. The scX and icX systems of human glioma appear to be useful models for study of the intrinsic multidrug resistance of glioma in vivo, and for studies of ways in which this multidrug resistance can be overcome.
We did not examine the glioma or glioma xenografts after chemotherapy, and it is unclear whether the overexpression of P-gp is inducible in glioma tumour cells. Further analysis of P-gp expression in xenografts after experimental treatment will provide more information on the acquired multidrug resistance of glioma in vivo.
